The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept.

阿达木单抗 乌斯特基努马 Golimumab公司 皮肤病科 观察研究 类风湿性关节炎 英夫利昔单抗 强直性脊柱炎 不利影响 甲氨蝶呤 肿瘤坏死因子抑制剂
作者
Ennio Lubrano,Antonio Spadaro,Antonio Marchesoni,Ignazio Olivieri,Raffaele Scarpa,Salvatore D'Angelo,Carlo Salvarani,Alessandro Mathieu,Alberto Cauli,Nicola Ferrara,Philip S. Helliwell
出处
期刊:Clinical and Experimental Rheumatology 卷期号:29 (1): 80-84 被引量:44
标识
摘要

Objectives. To investigate the effectiveness of etanercept on axial manifestations of a group of patients with established psoriatic arthritis (PsA). Methods. This was a multicentre observational study. PsA was classified based on the CASPAR criteria. Inclusion criteria were refractory PsA with axial manifestations and suitability for anti TNF-α therapy. Effectiveness was defined according to the ASAS response criteria (BASDAI: 50% relative or absolute change of 20mm and expert opinion in favour of continuation), and on the improvements of BASFI, anthropometric measures, PASI, ESR and CRP at 12 months. PASI 50 and 75 were also assessed, as well as the ACR20 and ACR50 response criteria for patients with peripheral arthritis. Comparisons between baseline and after 12-month treatment were done using the Wilcoxon signed rank test for the end-points considered. Results. The study included 32 patients (25/7 M/F; median age 51yrs; 25 th ―75 th percentiles: 34.5―58.7; median disease duration 14.5 yrs; 25 th ―75 th percentiles: 9.2―17.00). Effectiveness of etanercept was observed in 72% of patients for the BASDAI (p<0.001), in 68% for the BASFI (p<0.001), in 76% for ESR (p<0.001) and in 68% of patients for CRP (p<0.01). The PASI improved in 72% of patients treated (p<0.0001), while PASI50 and PASI 75 was reached in 81% and 55% of patients, respectively. ACR 20 and 50 was reached in 78 and 56% of patients with peripheral involvement respectively. Conclusion. The present study has shown that etanercept is effective on axial manifestations of established PsA, confirming the positive effects of anti TNF-α therapy on clinical manifestations of the disease.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Quenchingstar发布了新的文献求助10
1秒前
2秒前
adaddaaa完成签到,获得积分20
2秒前
2秒前
ing发布了新的文献求助10
3秒前
小慈完成签到,获得积分20
3秒前
鄂成危完成签到,获得积分10
3秒前
3秒前
jinl9587完成签到,获得积分10
4秒前
黄昏完成签到,获得积分10
6秒前
6秒前
wang发布了新的文献求助10
7秒前
李好人发布了新的文献求助10
7秒前
8秒前
ffgg12138发布了新的文献求助10
8秒前
9秒前
9秒前
果子嘿嘿完成签到,获得积分10
11秒前
雨寒完成签到,获得积分10
11秒前
ding应助kaiko采纳,获得20
11秒前
耍酷鼠标完成签到 ,获得积分0
12秒前
12秒前
jyl发布了新的文献求助10
12秒前
oceanao应助踏实谷蓝采纳,获得10
12秒前
华仔应助眼睛大亦玉采纳,获得10
13秒前
13秒前
13秒前
13秒前
小蘑菇应助Yhcir采纳,获得10
14秒前
zshhay完成签到 ,获得积分10
14秒前
仁爱的戒指完成签到 ,获得积分10
14秒前
14秒前
14秒前
雨寒发布了新的文献求助10
15秒前
yumemakase发布了新的文献求助10
15秒前
江沉晚吟完成签到 ,获得积分10
15秒前
16秒前
舒心新梅发布了新的文献求助10
18秒前
19秒前
密密麻麻M完成签到,获得积分10
19秒前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
Diagnostic immunohistochemistry : theranostic and genomic applications 6th Edition 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3155576
求助须知:如何正确求助?哪些是违规求助? 2806779
关于积分的说明 7870685
捐赠科研通 2465047
什么是DOI,文献DOI怎么找? 1312118
科研通“疑难数据库(出版商)”最低求助积分说明 629877
版权声明 601892